Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | RPA1 | P27694 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601766 | 0.89 | KDM4E (0.33) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL19635012 | 0.89 | KDM4E (0.33) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL19615953 | 0.83 | PRMT5 (0.32) | MCL1KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL21802173 | 0.81 | MCL1 (0.47) | MCL1KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL19618974 | 0.77 | MCL1 (0.35) | MCL1KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL19635267 | 0.75 | UCHL1 (0.31) | KDM4EALDH1A1HPGD | |
| SCHEMBL29601828 | 0.75 | UCHL1 (0.31) | KDM4EALDH1A1HPGD | |
| SCHEMBL19635268 | 0.72 | MCL1 (0.39) | MCL1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL29601778 | 0.72 | MCL1 (0.39) | MCL1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL19615314 | 0.72 | HTR6 (0.40) | KDM4EMEN1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | MCL1 62/4885KDM4E 1858/4885MEN1 114/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | MCL1 56/4885KDM4E 2044/4885MEN1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.